mTORC1 status dictates tumor response to targeted therapeutics. (Q38142727)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24065143 AND SRC:MED&resulttype=core&format=json

23 February 2020

title

mTORC1 status dictates tumor response to targeted therapeutics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24065143 AND SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24065143 AND SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Brendan D Manning

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24065143 AND SRC:MED&resulttype=core&format=json

23 February 2020

publication date

24 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24065143 AND SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24065143 AND SRC:MED&resulttype=core&format=json

23 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24065143 AND SRC:MED&resulttype=core&format=json

23 February 2020

issue

294

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24065143 AND SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

pe31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24065143 AND SRC:MED&resulttype=core&format=json

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

Common corruption of the mTOR signaling network in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

A growing role for mTOR in promoting anabolic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

Signal integration by mTORC1 coordinates nutrient input with biosynthetic output.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

The pharmacology of mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1126/SCISIGNAL.2004632

10.1126/SCISIGNAL.2004632

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24065143 AND SRC:MED&resulttype=core&format=json

23 February 2020

1 reference